Expert Opinion on Emerging Drugs

Papers
(The median citation count of Expert Opinion on Emerging Drugs is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity59
Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials35
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials22
Emerging synthetic drugs for the treatment of liver cirrhosis17
Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials15
Emerging therapeutics in Huntington’s disease14
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma14
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa14
Emerging therapies for dry eye disease12
Emerging drugs for the treatment of adult MOG-IgG-associated diseases12
Designing phase II clinical trials in Friedreich ataxia11
Emerging drugs for the treatment of alopecia areata10
Emerging topical drugs for the treatment of rosacea10
Emerging drugs for the treatment of myasthenia gravis10
Emerging antiviral therapies and drugs for the treatment of influenza9
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials9
Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma8
Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients8
Emerging biological therapies for the treatment of age-related macular degeneration7
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia7
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials7
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials7
Emerging drugs for the treatment of postsurgical pain6
Emerging drugs for the treatment of diabetic nephropathy6
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria6
Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials6
A review of phase II and III drugs for the treatment and management of endometriosis5
Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials5
Emerging drugs for the treatment of cutaneous T-cell lymphoma5
Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma5
Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials5
Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer5
Emerging drugs for the treatment of basal cell carcinoma5
A review of emerging factor XI inhibitors5
Emerging drugs for dementia with Lewy Bodies: a review of Phase II & III trials5
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention5
A review of emerging tyrosine kinase inhibitors as durable treatment of neovascular age-related macular degeneration4
Emerging drugs for the treatment of bladder storage dysfunction4
An update on emerging drugs for the treatment of hypercholesterolemia4
Emerging drugs for the prevention of migraine4
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma4
Emerging biological therapies for the treatment of malignant pleural mesothelioma4
Emerging drugs for the treatment of hepatocellular carcinoma4
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials4
Emerging injectable therapies for osteoarthritis4
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?4
Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia3
Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis3
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials3
Systemic mastocytosis: 2023 update on diagnosis and management in adults3
Recent advances in immune-based approaches for the treatment of esophagogastric cancer3
Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials3
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia3
Emerging drugs for the treatment of glaucoma: a review of phase II & III trials3
Emerging drugs in the treatment of chronic cough3
Emerging medicines to improve the basic defect in cystic fibrosis3
Emerging oral drug options for ulcerative colitis3
Emerging drugs for the treatment of inflammatory bowel disease3
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials3
Emerging therapies for Achondroplasia: changing the rules of the game2
Emerging hormonal agents for the treatment of prostate cancer2
Emerging therapies in the management of Irritable Bowel Syndrome (IBS)2
Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials2
Reviewing the role of emerging therapies in the ADHD armamentarium2
Cannabinoid treatment for the symptoms of autism spectrum disorder2
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials2
Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis2
Emerging tyrosine kinase inhibitors for head and neck cancer2
New drugs targeting calcitonin gene-related peptide for the management of migraines2
The future of antibody therapy in chronic lymphocytic leukemia2
Emerging drugs for the treatment of irritability associated with autism spectrum disorder2
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials2
Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials2
0.027486801147461